What are Artiva Biotherapeutics, Inc.'s total assets?

Artiva Biotherapeutics, Inc. (ARTV) holds $106.0M in total assets, down 44.6% year over year.

How much debt does Artiva Biotherapeutics, Inc. have?

Artiva Biotherapeutics, Inc. carries $10.3M in total debt against $87.8M of shareholders' equity, a debt-to-equity ratio of 0.12.

How much cash does Artiva Biotherapeutics, Inc. have?

Artiva Biotherapeutics, Inc. holds $21.4M in cash and equivalents.

Can Artiva Biotherapeutics, Inc. cover its short-term obligations?

Its current ratio is 8.16 — current assets exceed current liabilities.

Where does Artiva Biotherapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Artiva Biotherapeutics, Inc. ARTV Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23
Cash and cash equivalents	$27.16M-32.9%	$40.49M-24.7%	$53.76M-47.7%
Short-term investments	$81.31M-44.0%	$145.19M+519%	$23.47M—
Restricted cash	$461K+78.7%	$258K0.0%	$258K—
Prepaid expenses and other current assets	$4.59M+50.2%	$3.06M+180%	$1.09M—
Total current assets	$112.67M-40.3%	$188.63M+136%	$79.82M—
Property and equipment, net	$6.62M+3.9%	$6.37M-21.3%	$8.1M—
Accumulated depreciation	$8.46M+42.8%	$5.92M+67.7%	$3.53M—
Operating lease right-of-use assets	8%-1,379,399,992%	1,379,400,000%-275,300,000%	1,654,700,000%—
Other non-current assets	$458K+71.5%	$267K-31.9%	$392K—
Available-for-sale securities	——	——	——
Total assets	$130.94M-37.5%	$209.58M+99.4%	$105.11M—
Accounts payable	$4.45M+11.1%	$4.01M—	——
Accrued expenses	$7.57M+56.7%	$4.83M-39.7%	$8.02M—
Current portion of long-term debt	$44K-63.9%	$122K—	——
Operating lease liabilities, current	$3.02M-16.7%	$3.62M+0.6%	$3.6M—
Finance Lease Liability, Current	$44K-63.9%	$122K—	——
Total current liabilities	$13.09M+6.8%	$12.25M+0.2%	$12.23M—
Operating lease liabilities, non-current	$7.88M-25.4%	$10.57M-20.6%	$13.32M—
Operating Lease Liabilities (Total)	$10.9M-23.2%	$14.19M—	——
Total liabilities	$20.97M-8.6%	$22.94M-54.8%	$50.72M—
Common stock	3K0.0%	3K—	——
Additional paid-in capital	$440.41M+1.6%	$433.45M+2,183%	$18.99M—
Retained earnings	-$330.55M-34.0%	-$246.68M-36.1%	-$181.31M—
Accumulated other comprehensive income (loss)	$103K+180%	-$129K-142%	$308K—
Total stockholders' equity	$109.97M-41.1%	$186.64M+215%	-$162.02M-15.2%
Total liabilities and stockholders' equity	$130.94M-37.5%	$209.58M+99.4%	$105.11M—
Cash Cash Equivalents And Short Term Investments	——	——	——
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$67K-54.1%	$146K-79.8%	$724K—
Other Receivables	$67K-54.1%	$146K-79.8%	$724K—
Deferred Tax Assets and Other Non-Current Assets	$458K+71.5%	$267K-31.9%	$392K—
Net Investment in Lease	$10.53M-23.7%	$13.79M-16.6%	$16.55M—
Operating lease right-of-use assets	$10.53M-23.7%	$13.79M-16.6%	$16.55M—
Other non-current assets	$458K+71.5%	$267K-31.9%	$392K—
Property, plant and equipment at cost	$15.08M+22.6%	$12.29M+5.7%	$11.63M—
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$81.31M-44.0%	$145.19M+519%	$23.47M—
Operating Lease Right-of-Use Assets in Other Assets	$10.53M-23.7%	$13.79M-16.6%	$16.55M—
Software and Technology Licenses, Net	$458K+71.5%	$267K-31.9%	$392K—
Accrued Manufacturing Costs	$7.57M+56.7%	$4.83M+19.4%	$4.05M—
Other Commercial Liabilities	$9.6M+29.9%	$7.39M-7.8%	$8.02M—
Accrued Liabilities, Current	$9.6M+29.9%	$7.39M-7.8%	$8.02M—
Compensation and benefits	$7.57M+56.7%	$4.83M+19.4%	$4.05M—
Other accrued liabilities	$73K—	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——
Lease Liability Payments - Due Year Two	——	——	——
Lease Liability Payments - Due Year Three	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——
Operating Lease Liability Payments Due	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——
Total debt	$10.94M-23.8%	$14.35M-15.1%	$16.91M—
Common Stock Par Value Per Share	——	——	——
Common Stock Shares Issued	——	——	——
Convertible Preferred Stock Authorized Shares	——	——	——
Additional paid-in capital	$440.41M+1.6%	$433.45M+2,183%	$18.99M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$3K0.0%	$3K—	——
Shares Reserved for Future Issuance Under Stock Plans	7.1M+46.5%	4.9M-38.5%	7.9M—
Unrealized Gains on Investments	$108K+120%	$49K-84.1%	$308K—
Unrealized Losses on Investments (Before Tax)	$5K-97.2%	$178K-42.2%	$308K—
Cumulative Cost Basis	$15.08M+22.6%	$12.29M+5.7%	$11.63M—
Accrued Purchases Current	$149K-52.7%	$315K—	——
Accrued Research And Development Expenses Current	$858K-41.7%	$1.47M-48.5%	$2.86M—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$5K-97.2%	$178K-42.2%	$308K—
Gross Unrealized Gains	$108K+120%	$49K-84.1%	$308K—
Cash And Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost Excluding Interest After Allowance For Credit Loss	$107.91M-41.8%	$185.56M+142%	$76.66M—
Cash And Cash Equivalents At Fair Value And Available For Sale Debt Securities At Fair Value Excluding Accrued Interest	$108.01M-41.8%	$185.43M+141%	$76.97M—
Common stock, capital shares reserved for future issuance	$7.13M+46.5%	$4.86M-38.5%	$7.91M—
Common stock, par value (in dollars per share)	——	——	——
Common stock, shares authorized (in shares)	——	——	——
Common stock, shares issued (in shares)	——	——	——
Cumulative Gross Proceeds From Convertible Notes Derivative Instruments And Redeemable Convertible Preferred Stock	——	——	——
Available-for-sale securities, allowance for credit loss	——	——	——
Current maturities of long-term debt	$44K-63.9%	$122K—	——
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$212K-18.8%	$261K—	——
Lessee Operating Lease Liability Payments Due	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——
Movement Commitement Percentage	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.08+3.9%	$0.08-1.3%	$0.08—
Other accrued liabilities	$1.02M+32.3%	$774K-30.2%	$1.11M—
Preferred Stock, Shares Authorized	——	——	——
Stock Shares Authorized Temporary And Permanent Shares	——	——	——
Temporary Equity Par Or Stated Value Per Share	——	——	——
Remainder of Fiscal Year 2024	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Artiva Biotherapeutics, Inc.'s total assets?: Artiva Biotherapeutics, Inc. (ARTV) holds $106.0M in total assets, down 44.6% year over year.
How much debt does Artiva Biotherapeutics, Inc. have?: Artiva Biotherapeutics, Inc. carries $10.3M in total debt against $87.8M of shareholders' equity, a debt-to-equity ratio of 0.12.
How much cash does Artiva Biotherapeutics, Inc. have?: Artiva Biotherapeutics, Inc. holds $21.4M in cash and equivalents.
Can Artiva Biotherapeutics, Inc. cover its short-term obligations?: Its current ratio is 8.16 — current assets exceed current liabilities.
Where does Artiva Biotherapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.